HC Wainwright Reiterates "Buy" Rating for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $16.00 target price on the biopharmaceutical company's stock.

Several other brokerages have also recently weighed in on ESPR. JMP Securities reaffirmed a "market outperform" rating and issued a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. The Goldman Sachs Group reduced their target price on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a report on Thursday, April 17th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $5.00 target price on shares of Esperion Therapeutics in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Esperion Therapeutics has an average rating of "Hold" and a consensus price target of $6.42.

Esperion Therapeutics Price Performance

Shares of NASDAQ ESPR traded down $0.02 during midday trading on Friday, hitting $0.94. The company's stock had a trading volume of 3,006,760 shares, compared to its average volume of 5,643,095. The business's fifty day simple moving average is $1.36 and its two-hundred day simple moving average is $1.94. Esperion Therapeutics has a 1 year low of $0.82 and a 1 year high of $3.94. The firm has a market capitalization of $186.30 million, a price-to-earnings ratio of -1.47 and a beta of 0.86.

Hedge Funds Weigh In On Esperion Therapeutics

A number of institutional investors have recently modified their holdings of ESPR. Cibc World Markets Corp acquired a new position in shares of Esperion Therapeutics in the 4th quarter valued at $39,000. Synergy Asset Management LLC increased its holdings in shares of Esperion Therapeutics by 3,496.3% in the 1st quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 30,138 shares during the period. SJS Investment Consulting Inc. acquired a new position in shares of Esperion Therapeutics in the 4th quarter valued at $55,000. Crestline Management LP acquired a new position in shares of Esperion Therapeutics in the 4th quarter valued at $63,000. Finally, J.W. Cole Advisors Inc. purchased a new position in Esperion Therapeutics in the 4th quarter valued at $66,000. 47.39% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.